Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

BACKGROUND: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe s...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Ching, Travers, Duncan, Megan E., Newman-Eerkes, Tera, McWhorter, Mollie M. E., Tracy, Jeffrey M., Steen, Michelle S., Brown, Ryan P., Venkatasubbarao, Srivatsa, Akers, Nicholas K., Vignali, Marissa, Moorhead, Martin E., Watson, Drew, Emerson, Ryan O., Mann, Tobias P., Cimler, B. Melina, Swatkowski, Pamela L., Kirsch, Ilan R., Sang, Charles, Robins, Harlan S., Howie, Bryan, Sherwood, Anna
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325652/
https://ncbi.nlm.nih.gov/pubmed/32605647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07077-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares